Comparative Pharmacology
Head-to-head clinical analysis: AKOVAZ versus POLYSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKOVAZ versus POLYSPORIN.
AKOVAZ vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
5 mg intravenously once daily.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic
Topical Antibiotic